Affordable Access

ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.

Authors
  • 1
  • 1 Cancer, Metabolism, and Endocrine Research Department, Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom.
Type
Published Article
Journal
Cancer research
Publication Date
Volume
56
Issue
14
Pages
3287–3292
Identifiers
PMID: 8764123
Source
Medline

Abstract

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments